Salix gets good news from FDA on Relistor drug application

Posted by David Bracken on July 14, 2014 

Salix Pharmaceuticals announced Monday that federal regulators have signaled they will approve its drug Relistor for treatment of chronic pain in non-cancer patients.

The Food and Drug Administration is requiring some post-marketing observational studies, but will not require Salix and its partner Progenics Pharmaceuticals to submit additional data as part of its new drug application.

Salix expects to submit the additional information requested by the FDA within the next several weeks.

The FDA’s approval is for an injectable version of Relistor. Sterne Agee analyst Shibani Maholtra said in a note Monday that a future oral formulation of the drug is where the real value is likely to be. An approved oral formulation of Relistor could lead to $500 million to $750 million in annual sales, she estimated.

Salix shares were up about 2 percent in mid-morning trading Monday.

News & Observer is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere in the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from profanity, hate speech, personal comments and remarks that are off point. Thank you for taking the time to offer your thoughts.

Commenting FAQs | Terms of Service